18F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma

ObjectiveThe role of amino acid positron emission tomography (PET) in glioma grading and outcome prognostication has not yet been well established. This is particularly true in the context of the new WHO 2016 classification, which introduced a definition of glioma subtypes primarily based on molecular fingerprints. The aim of the present study was to correlate 3,4‑dihydroxy‑6‑[18F]‑fluoro-l‑phenylalanine (F-DOPA) uptake parameters with IDH mutation, 1p/19q status, and survival outcomes in patients with glioma.MethodsThe study population consisted of 33 patients (17 M/16 F, mean age: 46 ± 13 years) who underwent F-DOPA PET/CT for the evaluation of tumor extent before the start of chemo or radiotherapy. The presence of IDH mutation and 1p/19q status was assessed in all the cases. Tumor volume and semiquantitative uptake parameters, namely SUVmax, tumor-to-normal brain ratio and tumor-to-normal striatum ratio, were calculated for each tumor. Imaging-derived parameters were compared between patients stratified according to molecular fingerprints, using parametric or non-parametric tests, where appropriate. The Kaplan–Meier method was used to assess differences of overall survival (OS) and progression-free survival (PFS) between groups. PET parameters were also tested as prognostic factors in univariate Cox survival regression models.ResultsThere were 12 IDH-wild-type and 21 IDH-mutant patients. Stratification according to 1p/19q co-deletion resulted in 20 non-co-deleted and 13 co-deleted patients. Median follow-up time from PET/CT exam was 30.5 months (range 3.5–74 months). Semiquantitative uptake parameters did correlate neither with IDH mutation nor with 1p/19q status. Uptake was similar in low-grade and high-grade tumors, respectively. In addition, F-DOPA uptake parameters, macroscopic tumor volume, or tumor grade did not stratify OS, while a correlation between SUVmax and PFS was shown in the subgroup of astrocytomas. On the other hand, IDH mutation status and presence of 1p/19q co-deletion had a significant impact on survival outcomes. The prognostic value of IDH mutation status was also confirmed in the subgroup of patients with astrocytic tumors.ConclusionsF-DOPA uptake parameters do not correlate with tumor molecular and histological characteristics. The predictive value of PET-derived parameters on outcomes of survival is limited.

[1]  F. Giangaspero,et al.  Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers , 2013, Journal of Neuro-Oncology.

[2]  Y. Iwadate,et al.  Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography. , 2011, Journal of neurosurgery.

[3]  Val J Lowe,et al.  Biopsy validation of 18F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation: results of a prospective pilot study. , 2013, Neuro-oncology.

[4]  Ian Law,et al.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.

[5]  Kenji Hirata,et al.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging , 2015, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  Marie Blonski,et al.  A high 18F-FDOPA uptake is associated with a slow growth rate in diffuse Grade II-III gliomas. , 2017, The British journal of radiology.

[7]  Yasuo Iwadate,et al.  Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography , 2016, Journal of Neurology, Neurosurgery & Psychiatry.

[8]  T. Huber,et al.  Prognostic Value of O-(2-[18F]-Fluoroethyl)-L-Tyrosine-Positron Emission Tomography Imaging for Histopathologic Characteristics and Progression-Free Survival in Patients with Low-Grade Glioma. , 2016, World neurosurgery.

[9]  N. Galldiks,et al.  The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors. , 2018, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[10]  篠﨑 夏樹 Discrimination between low-grade oligodendrogliomas and diffuse astrocytoma with the aid of 11C-methionine positron emission tomography , 2012 .

[11]  Nadim Jon Shah,et al.  Amino acid PET and MR perfusion imaging in brain tumours , 2017, Clinical and Translational Imaging.

[12]  Paul Cumming,et al.  Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. , 2012, Neuro-oncology.

[13]  Nadim Jon Shah,et al.  Advances in neuro-oncology imaging , 2017, Nature Reviews Neurology.

[14]  Alexander R. Pico,et al.  Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. , 2015, The New England journal of medicine.

[15]  Gereon R Fink,et al.  Static and dynamic 18F–FET PET for the characterization of gliomas defined by IDH and 1p/19q status , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  E Guedj,et al.  IDH mutation is paradoxically associated with higher 18F-FDOPA PET uptake in diffuse grade II and grade III gliomas , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  A. Bizzi,et al.  Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  B. Scheithauer,et al.  The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.

[19]  M. Mamede,et al.  18F-DOPA uptake parameters in glioma: effects of patients' characteristics and prior treatment history. , 2018, The British journal of radiology.

[20]  Leland S. Hu,et al.  Biopsy validation of 18 F-DOPA PET and biodistribution in gliomas for neurosurgical planning and radiotherapy target delineation : results of a prospective pilot study , 2013 .

[21]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[22]  Karl-Josef Langen,et al.  Voxel-based 18F-FET PET segmentation and automatic clustering of tumor voxels: A significant association with IDH1 mutation status and survival in patients with gliomas , 2018, PloS one.